Company intelligence / Profile preview

FYR Diagnostics

Missoula, Montana, United States

Ownership: Private
Development stage: Other

Overview

FYR Diagnostics has developed the EV-Omics (EVO) platform, powered by its SPARCs technology, which enables the enrichment and analysis of disease-associated extracellular vesicles from blood to provide multiomic profiles (RNA, protein) for earlier, more precise diagnosis and disease monitoring in cancer, neurological disorders, and neonatal syndromes. Their approach has demonstrated potential for improved biomarker development and personalized patient care from screening through therapy selection and monitoring

Therapeutic areas: Infectious DiseasesOncologyNeurology
Modalities: DeviceDiagnostic platformAI-enabled multiomics (transcriptomics, proteomics)Extracellular vesicle-based assay
Industry: Molecular Diagnostics

Partnerships

Medicover (clinical diagnostic and precision medicine collaboration for North America)

Beyond the preview

Go deeper on FYR Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FYR Diagnostics.

Explore the full profile